Black Diamond Therapeutics (BDTX) furnishes Q3 2025 results update

Black Diamond Therapeutics (BDTX) furnished an 8-K announcing financial results for the three and nine months ended September 30, 2025.

Rhea-AI Filing Summary

Black Diamond Therapeutics (BDTX) furnished an 8-K announcing financial results for the three and nine months ended September 30, 2025. The company issued a press release with the details, which is included as Exhibit 99.1. The information was furnished, not filed, under Item 2.02.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BDTX announce in this 8-K?

The company announced financial results for the three and nine months ended September 30, 2025.

Where can I find the detailed BDTX results?

Details are in the press release furnished as Exhibit 99.1.

Is the information in this 8-K considered filed or furnished?

It is furnished under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act.

What is the date of the BDTX announcement?

November 6, 2025.

Which reporting period does this cover for BDTX (BDTX)?

It covers the three and nine months ended September 30, 2025.

What exchange lists BDTX common stock?

BDTX common stock trades on The Nasdaq Global Select Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 07:01 AM EST Learn about SEC filing dates

0001701541FALSE00017015412025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

BLACK DIAMOND

THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-39200			81-4254660
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

One Main Street, 14th Floor

Cambridge, MA 02142

(Address of principal executive offices, including zip code)

(617) 252-0848

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trade Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

BDTX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 6, 2025, Black Diamond Therapeutics, Inc. announced its financial results for the three and nine months ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.						Description
99.1						Press Release issued by Black Diamond Therapeutics, Inc., dated November 6, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Black Diamond Therapeutics, Inc.
Date: November 6, 2025			By:			/s/ Brent Hatzis-Schoch
						Brent Hatzis-Schoch
						Chief Operating Officer and General Counsel